HRT Explained: Types, Benefits, and What to Know

The WHI unnecessarily frightened women and left them suffering with very real symptoms, possibly preventing them from taking a life-changing, even life-prolonging treatment. HRT can have beneficial impacts on bones, brains, and heart — and many common fears around hormone therapy are not supported by the latest scientific evidence.

If you’re asking what HRT is, you’ve probably encountered a confusing mix of competing claims — that it’s dangerous, that it’s miraculous, that it’s only for severe symptoms, that everyone should be on it. The honest answer sits between those extremes, and the modern evidence base is much more settled than the cultural conversation suggests.

This guide walks through what hormone therapy actually is, the types of estrogen and progestogen used, the routes of administration, who current evidence supports treating, who shouldn’t be treated, and how to think about the timing of starting and stopping. It draws on the Menopause Society 2022 Hormone Therapy Position Statement, NICE Guideline NG23, and the major randomized trials (WHI, KEEPS, ELITE, DOPS) that have shaped current practice.

Key takeaways

HRT (hormone replacement therapy), now usually called menopause hormone therapy (MHT) or just hormone therapy (HT), is the use of estrogen — usually combined with a progestogen if you have a uterus — to manage menopause symptoms and certain long-term risks.

The Menopause Society 2022 Hormone Therapy Position Statement and NICE Guideline NG23 (updated November 2024) both endorse HT as first-line for moderate-to-severe vasomotor symptoms in symptomatic women under 60 or within 10 years of their final period.

Multiple estrogen formulations and routes exist: oral, transdermal (patches, gels, sprays), and vaginal. Transdermal is generally preferred for women with cardiovascular or thrombosis risk factors.

Progestogen options include micronized progesterone, synthetic progestins, and the levonorgestrel IUD. Choice affects both safety and tolerability.

The “timing hypothesis” — supported by the ELITE trial (Hodis 2016 in NEJM), KEEPS (Harman 2014 in Ann Intern Med), and reanalysis of WHI by age — supports starting HT near menopause rather than years later.

HT is not appropriate for everyone. Contraindications include known or suspected breast cancer, certain estrogen-dependent cancers, active or recent thromboembolism, active liver disease, and unexplained vaginal bleeding.

What HRT actually is

HRT stands for hormone replacement therapy, though the field has largely shifted to calling it menopause hormone therapy (MHT) or simply hormone therapy (HT). The change in terminology matters: “replacement” implies restoring premenopausal levels, which isn’t what modern HT does. Doses are typically lower, intended to manage symptoms and long-term risks rather than recreate reproductive-age hormone levels.

The core idea is straightforward. As ovarian function declines, estrogen production drops. That drop drives most menopause symptoms — vasomotor, urogenital, some cognitive and mood symptoms — and contributes to accelerated bone loss and adverse cardiovascular trajectories. Adding back estrogen (with a progestogen if you have a uterus, for endometrial protection) addresses those effects.

Modern HT is highly individualized: the estrogen, the dose, the route, the progestogen, the regimen (cyclical or continuous), and the duration are all decisions that should reflect your symptom profile, medical history, and preferences. The framing of “HT — yes or no” has largely been replaced by “which HT, how delivered, at what dose, for how long.”

Who current guidance supports treating

The two most authoritative current sources — the Menopause Society 2022 Position Statement and NICE Guideline NG23 — converge on the following framework.

HT is first-line treatment for moderate-to-severe vasomotor symptoms in symptomatic women who are:

Under age 60, OR

HRT is a treatment that is safe, very similar to your body's hormones, and doctor-recommended. There shouldn't be so much stigma around hormone therapy because the benefits outweigh the risks.

Within 10 years of their final menstrual period

This “window of opportunity” framing reflects the timing hypothesis (covered below) and the favorable benefit/risk profile in this group.

HT is appropriate for premature menopause (final period before age 40) and early menopause (final period before 45), typically continuing until at least the average age of natural menopause (around 51). Per the ESHRE 2016 POI guideline, women with POI face years of estrogen deficiency ahead of them, with cardiovascular, bone, and cognitive implications, and treatment in this group is about more than symptom relief.

Low-dose vaginal estrogen is first-line for genitourinary syndrome of menopause (GSM) at any age and has minimal systemic absorption. Per the Menopause Society’s 2020 GSM Position Statement, it is safe for the vast majority of women including most with histories of breast cancer when carefully selected with oncologist input.

HT is not first-line for women without symptoms simply for disease prevention. Use for fracture prevention is generally reserved for symptomatic women or those at high fracture risk who can’t tolerate other options.

For more on benefits specifically, see our HRT benefits guide.

Estrogen types and routes

The estrogen component of HT comes in multiple forms and delivery routes, each with different absorption, side effect, and risk profiles.

Estradiol (17β-estradiol)

Bioidentical estradiol — chemically identical to the estrogen your ovaries produced — is the most commonly used estrogen in modern HT. Available as oral tablets, transdermal patches, transdermal gels, transdermal sprays, and vaginal preparations.

Conjugated equine estrogens (CEE)

There's a lot of chatter around hormone replacement therapy. A lot of fear mongering, a lot of 'only I can do this for you the right way.' What I tell all my patients is that HRT is the replacing of the endocrine factors — the estrogen and progesterone — that have gone missing from a woman's body.

Derived from pregnant mare urine, CEE was the estrogen used in the original Women’s Health Initiative trial. Still available; somewhat less commonly prescribed in current practice as estradiol has become more available.

Estriol

A weaker estrogen sometimes used in vaginal preparations, particularly in Europe.

Routes of administration

Oral. Tablets taken daily. Convenient. First-pass liver metabolism affects clotting factors and triglycerides, which is why oral estrogen carries a higher VTE (blood clot) risk than transdermal.

Transdermal (patches). Applied once or twice weekly. Bypasses first-pass metabolism. Lower VTE risk than oral. Generally preferred for women with cardiovascular risk, migraine with aura, obesity, smoking history, or any baseline thrombosis risk.

Transdermal (gels and sprays). Daily application to the skin. Similar systemic risk profile to patches. Allows fine dose adjustment.

Vaginal (low-dose). Creams, rings (lower dose), tablets. Used for GSM specifically. Minimal systemic absorption at low doses.

For most women starting HT today, transdermal estradiol is the default starting point unless oral has a specific advantage (cost, tolerance, patient preference). The lower VTE risk profile of transdermal is part of why the safety conversation has shifted significantly since the original WHI publication.

Progestogen options

For women with an intact uterus, estrogen alone causes endometrial hyperplasia and increases endometrial cancer risk. A progestogen is added for endometrial protection. Women who have had a hysterectomy generally don’t need progestogen and can use estrogen alone.

Micronized progesterone

Bioidentical progesterone, taken orally (usually 100 mg continuous or 200 mg cyclical). Increasingly the preferred progestogen in current practice. Tends to be better tolerated than synthetic progestins; some women find it improves sleep. The DOPS trial (Schierbeck 2012 in BMJ) used estradiol plus norethisterone acetate, but the broader pattern in current practice has shifted toward micronized progesterone where available and affordable.

Synthetic progestins

Multiple options — medroxyprogesterone acetate (used in the original WHI), norethisterone acetate, dydrogesterone, drospirenone, levonorgestrel. Synthetic progestins vary in androgenic activity, metabolic effects, and tolerability. Choice depends on availability, side effect profile, and clinician preference.

Levonorgestrel IUD

Provides effective endometrial protection alongside systemic or transdermal estrogen, with minimal systemic progestogen exposure. Useful for women who don’t tolerate oral progestogens or who want contraception alongside HT in perimenopause.

Tibolone

A synthetic steroid with mixed estrogenic, progestogenic, and androgenic activity. Used outside the United States in some regions; not FDA-approved in the US.

Regimens: cyclical vs continuous

In continuous combined HT, both estrogen and progestogen are taken daily without a break, and there is no scheduled bleeding. This is the typical regimen for postmenopausal women.

In cyclical (sequential) HT, estrogen is taken daily and progestogen is added for 12-14 days each month, producing a monthly withdrawal bleed. Often used in late perimenopausal women still cycling, or in early postmenopausal women where continuous combined regimens may cause irregular bleeding.

The transition from cyclical to continuous is typically considered after a woman is clearly postmenopausal. Bleeding patterns on HT need monitoring; persistent or unexpected bleeding warrants evaluation.

The timing hypothesis

The single most important shift in HT thinking over the past two decades has been the timing hypothesis: the idea that HT started near menopause has a meaningfully different benefit/risk profile than HT started years later.

The original Women’s Health Initiative trial (Rossouw 2002 in JAMA) reported increased risks of breast cancer, cardiovascular events, and stroke with HT — findings that dramatically reduced HT prescribing globally and that have shaped the cultural conversation about hormone therapy ever since. But the women enrolled in WHI had a mean age of 63 and were on average a decade past menopause. The trial was designed to test whether HT could prevent chronic disease in older women, not whether it could safely manage symptoms in women near menopause. The headline findings were extrapolated to all HT users in ways that subsequent analyses suggest were not warranted.

Subsequent age-stratified analyses (Manson 2017 in JAMA, 18-year follow-up) showed the risk profile was substantially different in younger women. Women aged 50-59 at randomization had favorable mortality trends, no increased coronary heart disease risk in the estrogen-alone arm, and overall a much more balanced benefit/risk picture than the original headline numbers suggested. The WHI follow-up data have also clarified that the original combined HT findings were driven heavily by the medroxyprogesterone acetate component, with current synthetic progestins and micronized progesterone showing different patterns.

Trials specifically designed around timing have supported the hypothesis. ELITE found that estradiol slowed atherosclerosis progression in women within 6 years of menopause, but not in women 10+ years out. KEEPS found that HT started in recently menopausal women was well tolerated and improved symptoms without adverse cardiovascular signal over 4 years. The DOPS trial of early-postmenopausal women showed a reduction in cardiovascular events and fractures with 10 years of HT.

The current synthesis: HT initiated near menopause (under 60 or within 10 years of final period) in appropriately selected women has a favorable benefit/risk profile. HT initiated 10+ years after menopause carries a less favorable profile and is generally not recommended for symptom relief unless symptoms are severe and other options have failed. The “window of opportunity” framing is now central to how the Menopause Society and NICE structure their guidance.

For more on the WHI history and current synthesis, see our Is HRT safe pillar.

Benefits

The evidence-based benefits of HT in appropriately selected women include:

Vasomotor symptoms. HT is the most effective treatment for hot flashes and night sweats. Reductions of 70-90% are typical, often within weeks. No other treatment matches this effect size.

Sleep. Improvements in sleep — both directly via reduced night sweats and possibly via direct effects on sleep architecture.

Mood. Modest improvements in mood symptoms during the transition, particularly when vasomotor symptoms are also present. Not a primary depression treatment.

Genitourinary syndrome. Both systemic HT and (more specifically) low-dose vaginal estrogen are highly effective for vaginal dryness, painful sex, urinary urgency, and recurrent UTIs.

Bone. Reduces fracture risk. DOPS showed a roughly 50% reduction over 10 years of HT initiated early after menopause. HT is approved for fracture prevention in women at risk who can’t tolerate other options.

Cardiovascular (in early-menopausal women). ELITE and DOPS suggest a favorable cardiovascular profile when HT is started near menopause. This is not the same as recommending HT for primary cardiovascular prevention in asymptomatic women — that’s not current guidance — but it does mean the older “HT increases cardiovascular risk” framing is too simple.

Cognition. KEEPS-Cog (Gleason 2015 in PLoS Medicine) found HT started near menopause was cognitively neutral over 4 years — neither helping nor harming. WHIMS (Shumaker 2003) found cognitive harm in women starting HT at age 65+, supporting the timing hypothesis on cognition as well.

Risks

The evidence-based risks of HT include:

Breast cancer. Combined estrogen + progestogen HT is associated with a small absolute increase in breast cancer risk after several years of use, varying by progestogen type. Estrogen alone (in women who have had a hysterectomy) does not appear to increase breast cancer risk and in WHI was associated with reduced breast cancer incidence. Absolute risks are small in eligible women near menopause; risk needs to be weighed alongside individual baseline risk and competing benefits.

Venous thromboembolism (VTE). Oral estrogen approximately doubles VTE risk; transdermal estrogen does not appear to meaningfully raise VTE risk. This is one of the strongest reasons transdermal is preferred for women with any thrombosis risk factors.

Stroke. Oral estrogen is associated with a small increased risk of stroke, particularly in older women. Transdermal preparations appear lower-risk.

Gallbladder disease. Oral estrogen is associated with increased gallbladder disease risk; transdermal is less so.

Endometrial cancer. Estrogen alone increases endometrial cancer risk in women with a uterus. Adding a progestogen for endometrial protection prevents this — which is why combined regimens are used in women with intact uteri.

The Menopause Society 2022 statement frames the overall risk picture using absolute risk per 1,000 women per year, which is much more useful than the original WHI’s relative risk framing. For a woman near menopause with significant symptoms and no contraindications, the absolute risk increase from HT is small in most categories and is often outweighed by symptom benefit and cardiovascular and bone benefit.

Contraindications

HT is not appropriate for everyone. Standard contraindications include:

Known or suspected breast cancer (current or previous)

Known or suspected estrogen-dependent malignancy

Active or recent venous thromboembolism (DVT, PE)

Active or recent arterial thromboembolism (stroke, MI)

Active liver disease or significant hepatic impairment

Unexplained vaginal bleeding (needs workup first)

Known or suspected pregnancy

Untreated endometrial hyperplasia

Some conditions are relative contraindications or require special consideration rather than blanket exclusion. Migraine with aura — historically considered a contraindication based on oral contraceptive data — is now generally acceptable with transdermal estrogen at HT doses, though the decision involves weighing individual stroke risk factors. High cardiovascular risk and BRCA-positive status without prior risk-reducing surgery warrant careful individualized assessment. A family history of VTE without personal history is not by itself a contraindication but raises the case for transdermal over oral and for thrombophilia workup before initiation. Gallbladder disease history weighs in favor of transdermal preparations. Active migraine without aura, well-controlled hypertension, and successfully treated breast cancer in the distant past (with oncologist input) all sit in the discussion zone rather than the automatic-no zone.

For women with a personal history of breast cancer, vaginal estrogen at the lowest effective dose for GSM has the strongest safety record and is often acceptable with oncologist consultation, even though systemic HT generally is not. See our is vaginal estrogen safe guide for details.

This is one of the reasons HT decisions warrant a clinician familiar with current evidence rather than a checkbox approach. The picture is more nuanced than “yes or no.”

Bioidentical hormones and compounded products

“Bioidentical” is a term that means chemically identical to the hormones your body produces — estradiol, progesterone. FDA-approved bioidentical preparations (estradiol patches, gels, sprays; micronized progesterone) are widely available and are the foundation of most modern HT.

Compounded “bioidentical” hormone preparations — including pellet therapy, custom-mixed creams, and salivary-test-titrated regimens — are a different category. The Menopause Society 2022 Position Statement specifically does not endorse compounded products. Concerns include lack of FDA oversight, variable potency, unverified safety profile, and marketing claims that often exceed evidence. Pellet therapy in particular has raised concerns about supraphysiologic estrogen levels and difficulty adjusting dose.

For more, see our bioidentical hormones vs. traditional HRT guide.

How long to stay on HT

This is one of the most asked-about questions and the answer has changed substantially in the past two decades.

The older guidance — “use the lowest dose for the shortest duration” — has been substantially revised. Current guidance from the Menopause Society 2022 statement and NICE NG23 supports continuing HT as long as benefits outweigh risks for the individual, with periodic reassessment (typically annual). The shift reflects the recognition that vasomotor symptoms last longer than was previously assumed — SWAN data show a median total duration of 7.4 years — and that prematurely stopping HT often produces a return of symptoms that prompted the original prescription.

There is no fixed time limit on HT use. Some women use HT for a few years; some use it for a decade or more. The decision involves ongoing assessment of symptom burden, evolving individual risk factors, and patient preference. For women who started HT near menopause and have continued well into their 60s, the ongoing benefit/risk picture often remains favorable, though periodic reassessment is appropriate.

When stopping HT, symptoms (particularly vasomotor) often return. Some women have a smooth resolution; others have a marked recurrence that prompts restarting. Tapering vs. stopping cold doesn’t appear to make a meaningful difference in whether symptoms return, though tapering may make the experience more manageable.

What this means for you

The framework for thinking about HT today is much more individualized than it was 20 years ago. The question is no longer “is HT safe in general?” but “is HT appropriate for me, given my symptoms, my history, and my preferences — and if so, which formulation, dose, route, and regimen?”

For most women with moderate-to-severe vasomotor symptoms who are under 60 or within 10 years of menopause and don’t have contraindications, current evidence supports HT as a reasonable option with a favorable benefit/risk profile. For women with significant cardiovascular, breast cancer, or thrombosis risk, the picture is more complex but not automatically negative — transdermal estrogen and careful progestogen selection often broaden eligibility.

For women outside the timing window, with significant contraindications, or who prefer non-hormonal approaches, effective options exist: fezolinetant, SSRIs/SNRIs, gabapentin, CBT, and structured lifestyle change all have evidence. See our Veozah, medication for hot flashes, and natural remedies for menopause guides.

The clinician conversation is the bottleneck for most women, and one of the more common barriers is finding a clinician familiar with current evidence rather than the outdated framing of the early 2000s. Our talking to your doctor about menopause guide walks through how to advocate for an evidence-based conversation.

When to talk to your doctor

Bring it up if vasomotor symptoms are disrupting sleep, work, or daily function; you have urogenital symptoms (vaginal dryness, painful sex, urinary urgency, recurrent UTIs); you’re considering HT and want to understand whether it’s appropriate; you’re already on HT and want to reassess; you have specific risk factors and want to understand the implications; or your final period occurred before age 45, especially before 40 (POI workup and management).

For a structured way to prepare, our talking to your doctor about menopause guide walks through what to bring and how to advocate for yourself.

Frequently asked questions

Sources

Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.

Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women’s Health Initiative randomized trials. JAMA. 2017;318(10):927-938.

Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Annals of Internal Medicine. 2014;161(4):249-260. (KEEPS.)

Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. New England Journal of Medicine. 2016;374(13):1221-1231. (ELITE.)

Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345:e6409. (DOPS.)

Gleason CE, Dowling NM, Wharton W, et al. Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled KEEPS-Cognitive and Affective Study. PLoS Medicine. 2015;12(6):e1001833.

Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: WHIMS. JAMA. 2003;289(20):2651-2662.

Webber L, Davies M, Anderson R, et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Human Reproduction. 2016;31(5):926-937.

The Menopause Society. The 2020 Genitourinary Syndrome of Menopause Position Statement. Menopause. 2020;27(9):976-992.

The Menopause Society. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.

National Institute for Health and Care Excellence. Menopause: identification and management (NG23). Updated November 2024.

Disclaimer

This article is for educational purposes and does not constitute medical advice. Always consult a qualified healthcare provider for guidance on your specific situation. Hormone therapy is a prescription treatment that requires individualized assessment of medical history, current health status, and risk factors. It is not appropriate for everyone. Contraindications include known or suspected breast cancer, certain estrogen-dependent cancers, active or recent venous or arterial thromboembolism, active liver disease, unexplained vaginal bleeding, and pregnancy. This article does not provide specific dosing guidance; dose, route, and regimen decisions belong to your clinician.